|
Friday, 05 August 2011 00:07 |
|
 Pfizer Inc. (PFE) agreed to lend its Quigley unit as much as $65 million in cash to extend the subsidiary’s bankruptcy, potentially giving Pfizer further protection against claims for asbestos-related health issues.
|
|
Read more...
|
|
Thursday, 04 August 2011 00:30 |
 ULURU Inc. (NYSE AMEX: ULU), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced it has completed a $125,000 convertible debt financing with Kerry P. Gray, the Company's Chairman, President, and Chief Executive Officer. The Company intends to use the funds for general corporate purposes.
|
|
Read more...
|
|
Thursday, 04 August 2011 00:09 |
|
 AmerisourceBergen is looking to buy pharmaceutical packaging and distribution assets using some of the $2bn (€1.4bn) it has accumulated.
|
|
Read more...
|
|
Wednesday, 03 August 2011 00:06 |
 PDI, Inc. (Nasdaq: PDII) today announced that, through a newly formed business unit, Interpace BioPharma, LLC, it has entered into a two-and-a-half-year, fee-for-service agreement with a pharmaceutical company to market in the United States and its territories a treatment for pain of the knee.
|
|
Read more...
|
|
Tuesday, 02 August 2011 00:27 |
 Amgen (NASDAQ: AMGN) reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010.
|
|
Read more...
|
|
Monday, 01 August 2011 16:10 |
|
 AstraZeneca Plc has settled almost all lawsuits that claimed its antipsychotic drug Seroquel causes diabetes in some users for a total of $647 million.
|
|
Read more...
|
|
Monday, 01 August 2011 16:04 |
 Roka Bioscience, Inc. announced today that it recently completed a Series C round of equity financing, raising $20 million in new capital. The financing brings the total amount raised to $57.2 million since the company's formation in September 2009.
|
|
Read more...
|
|
Saturday, 30 July 2011 00:52 |
 Illumina, Inc. (ILMN: News ), Tuesday said its profit for the second quarter improved from a year ago, as revenues grew 36 percent, though gross margins declined. As well, both adjusted earnings and revenues for the quarter came in ahead of Street estimates.
|
|
Read more...
|
|
Saturday, 30 July 2011 00:02 |
 Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has closed the acquisition of Paddock Laboratories, Inc. ("Paddock"), a privately-held, Minneapolis-based pharmaceutical manufacturer of generic Rx pharmaceuticals and OTC specialty products for approximately $540 million in cash.
|
|
Read more...
|
|
Friday, 29 July 2011 00:32 |
|
 Valeant Pharmaceuticals International Inc. (VRX), the drugmaker that has pursued more than 10 acquisitions in the past year, approached Sweden’s Meda AB (MEDAA) about a takeover, said two people with knowledge of the matter.
|
|
Read more...
|
|
|
Friday, 05 August 2011 00:03 |
|
 Private equity firm Czura Thornton Ltd. has put Chiltern International Ltd., a clinical research company, up for sale for more than 200 million pounds ($329 million), the Mail on Sunday reported, without saying where it got the information.
|
|
Read more...
|
|
Thursday, 04 August 2011 00:17 |
 Auxilium Pharmaceuticals, Inc. /quotes/zigman/92812/quotes/nls/auxl AUXL +1.01% , a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended June 30, 2011. For the second quarter of 2011, Auxilium reported net revenues of $65.9 million compared to net revenues of $50.5 million in the second quarter of 2010.
|
|
Read more...
|
|
Wednesday, 03 August 2011 00:59 |
 Shionogi & Co., Ltd. to AcquireChina-based C&O Pharmaceutical Technology (Holdings) LimitedOsaka, Japan, August 1, 2011 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), Leo Star Development Limited (Incorporation: British Virgin Islands; hereafter “Leo Star”), the largest shareholder of the China-based Singapore listed company, C&O Pharmaceutical Technology (Holdings) Limited (Incorporation:
|
|
Read more...
|
|
Wednesday, 03 August 2011 00:04 |
|
Pfizer Inc NYSE:PFE recently announced that the US Food and Drug Administration has issued a 90-day extension to the action date for the Company’s supplemental Biologics License Application (sBLA) for use of Prevnar 13® in adults aged 50 and older.
|
|
Read more...
|
|
Tuesday, 02 August 2011 00:21 |
 Merlin Nexus and New Leaf Venture Partners (NLV Partners), stockholders in Icagen, Inc. (Nasdaq: ICGN), disclosed today a letter submitted to the Icagen Board contesting the Company’s planned acquisition by Pfizer Inc (NYSE: PFE).
|
|
Read more...
|
|
Monday, 01 August 2011 16:05 |
 Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File letter in response to the company’s New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy which was submitted in May 2011.
|
|
Read more...
|
|
Monday, 01 August 2011 16:02 |
|
Pfizer Inc. (PFE) plans to send out information on its infant-nutrition unit to potential bidders in September, kicking off an auction that may fetch as much as $10.5 billion, said people with knowledge of the process.
|
|
Read more...
|
|
Saturday, 30 July 2011 00:05 |
 Novaliq GmbH a drug delivery company with focus on technologies for poorly soluble drugs for ophthalmic and topical applications has today announced the successfully completion of a financing round of € 2.3 Mio. Since its foundation in the year 2004 the company has raised € 9,3 Million in three finance rounds.
|
|
Read more...
|
|
Friday, 29 July 2011 00:37 |
|
Peloton Therapeutics, Inc., an early-stage cancer drug discovery and development company, has announced the completion of an $18 million Series A financing. Led by The Column Group and joined by Remeditex Ventures and Peter O'Donnell, Jr., the Series A funds supplement a recently awarded $11 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
|
|
Read more...
|
|
Friday, 29 July 2011 00:19 |
 Trius Therapeutics, Inc. and Bayer Pharma AG today announced that they have signed an exclusive agreement to develop and commercialize Trius' lead Phase 3 antibiotic, torezolid phosphate (torezolid), in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East, excluding North and South Korea.
|
|
Read more...
|
|
